Literature DB >> 35104621

Drug repositioning trends in rare and intractable diseases.

Ryuichi Sakate1, Tomonori Kimura2.   

Abstract

Drug repositioning (DR) is an effective way for developing drugs for rare and intractable diseases (RIDs). Preparation of the ontology is essential for drug development in RIDs, in which disease names have been inconsistently used worldwide. Ontology-based analysis of clinical trial data revealed that DR occurs actively in RIDs. Drugs and their target genes are keys to explore repositionable drugs, because shared target genes between diseases indicate a common mechanism of drug action. This approach visualizes a DR landscape that facilitates drug development. Here, we review the current situation of ontology in RIDs, the trends in drug development, and an efficient strategy for DR based on drug target gene information.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Clinical trials; Drug repositioning; Drug repurposing; Drug target genes; Ontology; Rare and intractable diseases

Mesh:

Year:  2022        PMID: 35104621     DOI: 10.1016/j.drudis.2022.01.013

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   8.369


  3 in total

1.  Drug repurposing: An effective strategy to accelerate contemporary drug discovery.

Authors:  Peng Zhan; Bin Yu; Liang Ouyang
Journal:  Drug Discov Today       Date:  2022-05-31       Impact factor: 8.369

2.  Identification of Potential Parkinson's Disease Drugs Based on Multi-Source Data Fusion and Convolutional Neural Network.

Authors:  Jie Liu; Dongdong Peng; Jinlong Li; Zong Dai; Xiaoyong Zou; Zhanchao Li
Journal:  Molecules       Date:  2022-07-26       Impact factor: 4.927

Review 3.  Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG).

Authors:  Sandra Brasil; Mariateresa Allocca; Salvador C M Magrinho; Inês Santos; Madalena Raposo; Rita Francisco; Carlota Pascoal; Tiago Martins; Paula A Videira; Florbela Pereira; Giuseppina Andreotti; Jaak Jaeken; Kristin A Kantautas; Ethan O Perlstein; Vanessa Dos Reis Ferreira
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.